There are 3484 resources available
Biomarker-selected therapy: Progress or delusion?
Presenter: Paul Baas
Session: Open questions in the management of mesothelioma
Resources:
Slides
Webcast
Peptide-based cancer vaccines
Presenter: Juliane Walz
Session: New targets on the horizon
Resources:
Slides
Webcast
Drug sensitivity testing in blood cancer
Presenter: Thorsten Zenz
Session: Next generation diagnostics of blood cancer: An optimistic view on the future of cancer testing
Resources:
Slides
Webcast
India’s approach to advance access to cancer medicines
Presenter: Manju Sengar
Session: Making essential cancer drugs affordable
Resources:
Slides
Webcast
2360O - The double antibody drug conjugate (DAD) phase I trial: Sacituzumab govitecan (SG) plus enfortumab vedotin (EV) as ≥ second-line therapy for metastatic urothelial carcinoma (mUC)
Presenter: Bradley McGregor
Session: Proffered Paper session 1 - Genitourinary tumours, non-prostate
Resources:
Abstract
Slides
Webcast
LBA71 - A multi-centre open-label randomized phase II study of osimertinib with and without ramucirumab in TKI-naïve EGFR-mutant metastatic NSCLC (RAMOSE trial interim analysis)
Presenter: Xiuning Le
Session: Mini oral session 1 - NSCLC, metastatic
Resources:
Abstract
Slides
Webcast
New approaches in cancer vaccines
Presenter: Sjoerd van der Burg
Session: Advancing strategies for cancer immunotherapy
Resources:
Slides
Webcast
Q&A and Discussion
Presenter: All Speakers
Session: Unravelling choices for adjuvant endocrine therapy in HR+ early breast cancer
Resources:
Slides
Webcast
Preoperative or postoperative radiation for mesothelioma
Presenter: Kenneth Rosenzweig
Session: Open questions in the management of mesothelioma
Resources:
Slides
Webcast
Mutant specific inhibitors
Presenter: Alexander Drilon
Session: New targets on the horizon
Resources:
Slides
Webcast